This clinical trial is focused on studying the effects of a medication called Zalunfiban in patients who have experienced an acute heart attack, specifically a type known as ST-elevation myocardial infarction (STEMI). STEMI is a serious condition where a part of the heart muscle is suddenly blocked from receiving blood, leading to chest pain and changes in the heart’s electrical activity. The study will compare the effects of a single injection of Zalunfiban with a placebo, which is an inactive substance, to understand its safety and effectiveness.

The purpose of the study is to assess the outcomes of patients 30 days after receiving the treatment. Participants will receive a single injection of Zalunfiban or a placebo before they reach the hospital. The study will monitor the patients for any major health events, such as death, stroke, or another heart attack, as well as any bleeding incidents, which are important safety concerns. The study aims to provide insights into how Zalunfiban might help improve the condition of patients with STEMI when administered early.

Throughout the study, patients will be observed for any side effects or reactions at the injection site. The trial will also track the patients’ recovery and any additional treatments they might need. This research is important for understanding how Zalunfiban can be used to potentially improve outcomes for people experiencing a heart attack, offering new possibilities for treatment in emergency situations.